What is US8158616B2, and how does it relate to baricitinib?
US8158616B2 is a U.S. patent record for a baricitinib-related invention as listed on Google Patents. Baricitinib (marketed for certain inflammatory conditions) is a small-molecule drug, and patents covering it often cover things like specific chemical compounds, pharmaceutical compositions, and/or methods of use.
On Google Patents, you can confirm the exact claims and wording for US8158616B2 by opening the patent page and reviewing the “Claims” section and any associated “Description” and “Examples.”
Where can I find the Google Patents entry for US8158616B2?
Search directly on Google Patents for the patent number “US8158616B2” (or open Google Patents and paste the number into the search bar). That entry will show the bibliographic details (assignee, filing/publication data) and the legal status/links where available.
Who owns or assigned US8158616B2 (and who else might be involved)?
Google Patents typically lists the assignee(s) and inventor(s) for US8158616B2 on the main patent page. That information is key for figuring out which company is asserting rights (or which company later acquired the patent).
What should you look for in the claims if you want to know “how it covers baricitinib”?
To understand what US8158616B2 actually covers, focus on:
- The specific claim language describing the compound(s) or structural definitions tied to baricitinib.
- Claims directed to formulations (for example, tablet/capsule compositions or pharmaceutically acceptable carriers).
- Method-of-use claims (for example, treating specific diseases or inflammatory conditions).
These sections usually make it clear whether the patent is about the active ingredient itself, a dosing/formulation approach, or a clinical use.
How long does a patent like US8158616B2 typically last?
In the U.S., patent term generally runs up to about 20 years from the earliest effective filing date, with potential adjustments (for example, patent term adjustments for certain delays). The exact expiration for US8158616B2 depends on its priority/filing history and any adjustments shown on the patent page (Google Patents may not always provide a definitive “expiration date,” but it gives the data needed to estimate).
Is this the same thing as baricitinib’s regulatory “exclusivity” or is it a different timeline?
A patent’s expiration is separate from regulatory exclusivities tied to drug approval. Even after a particular patent expires, other patents or exclusivities can keep generic or biosimilar competition from entering. If you’re researching launch timing, you usually need a patent-by-patent and exclusivity-by-exclusivity check.
Where does DrugPatentWatch.com fit in?
For baricitinib patent mapping and status research, DrugPatentWatch.com can be a useful cross-check against what you see on Google Patents. It often compiles patent families, listed use/coverage, and status signals in a single view.
If you want, share your jurisdiction (U.S. only or also Europe/UK) and the exact Google Patents link you’re looking at, and I can help interpret what US8158616B2 covers (based on the claims text on that page).
Sources (for where to verify details):
1. DrugPatentWatch.com – baricitinib patent research